---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Care management intervention strategies"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Care management intervention strategies. Topics: Multidisciplinary follow-up and baseline assessment; Recommended monitoring of swallowing, hearing, and cognition in the 2025 guideline; Recommended surveillance schedule in GeneReviews; Care coordination and social work support; 4 further topics. 8 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Multidisciplinary follow-up and baseline assessment

> “Statement #14: Patients with NPC exhibit multisystem disease manifestations and benefit from holistic, multidisciplinary follow‐up from physicians and allied HCPs with experience in this condition.”
> “A baseline assessment at diagnosis is required to determine the current level of disease severity and retrospectively estimate the rate of progression”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-2"></a>

### Recommended monitoring of swallowing, hearing, and cognition in the 2025 guideline

> “The presence of dysphagia, aspiration and response to therapy should be documented at diagnosis and then every 6 months in children and every 12 months in adults if the patient is asymptomatic with stable disease.”
> “Hearing assessments should be performed at the time of diagnosis and every 12 months to document the presence of hearing loss.”
> “Individuals with NPC benefit from regular evaluation of their cognitive function (at diagnosis and every 12 months), and consideration should be given to changes in their cognitive ability that may impact independence/school/work and daily living activities.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-3"></a>

### Recommended surveillance schedule in GeneReviews

| Concern | Evaluation | Frequency |
| --- | --- | --- |
| Interval medical history | “Establish rate of disease progression.” | “Every 6 mos” |
| NPC clinical severity score | “Document progression & response to therapy of key disease features.” | “Every 6 mos” |
| Hearing impairment | “Audiometry for new-onset hearing loss or its progression” | “Every 12 mos” |
| Nutrition and feeding | “Document nutritional status, presence/progression of dysphagia, & aspiration risk.” | “Every 6 mos in children; in adults, frequency could be ↓ to every 12 mos if asymptomatic & disease is stable” |

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.2.4-4"></a>

### Care coordination and social work support

> “Coordinate care to manage multiple subspecialty appointments, equipment, medications, & supplies.”
> “Ensure appropriate social work involvement to connect families w/local resources, respite, & support.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

> “Disease‐specific patient care is primarily conducted within the tertiary setting, with allied health, disability support services and general medical care occurring in a variety of external settings.”
> “The MDT should strive to provide individuals with NP‐C and their carers with a single treatment plan that accounts for regular assessments, examinations and medications.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.4-5"></a>

### Proactive swallowing surveillance for silent aspiration

> “Our findings support proactive swallowing surveillance in patients with NPC1, including consideration of routine instrumental evaluations (VFSS or FEES) even in the absence of overt clinical symptoms, particularly as neurologic severity increases.”

Source: [Solomon et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539892/)

<a id="topic-2.2.2.4-6"></a>

### Transition to adult services and palliative care planning

> “Statement #20: Most children with late infantile and juvenile onset NPC are expected to reach adulthood with complex medical and psychosocial needs.”
> “The transition from pediatric to adult services should begin early and requires appropriate services in the community to provide a seamless transition from childhood to adult life.”
> “Statement #21: Specialist center care providers, family physicians/pediatricians, and local palliative care services should develop close working links to support individuals and families with NPC throughout their lifespan.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.4-7"></a>

### Audiology monitoring during LEMBAZ treatment described for families

> “Before you or your child starts LEMBAZ, your healthcare provider will do a complete hearing evaluation (audiology evaluation) to establish baseline hearing levels.”
> “If the dosage level stays the same for 2 doses in a row, or the maximum dose is reached, hearing evaluations will be done once a month until 3 stable results in a row are obtained.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.4-8"></a>

### Peer support for families considering LEMBAZ

> “Recognizing the value of families learning from one another, Beren has also launched the Caregiver Ambassador Program to connect families considering LEMBAZ with caregivers who have firsthand experience with treatment.”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
